ABSTRACT
This study examined five central issues regarding the classification of attention-deficit hyperactivity disorder (ADHD) in an epidemiologically derived sample of primary school children. A monothetic schema (DSM-III) differed from a polythetic-only schema (DSM-III-R) by having a higher frequency of comorbid conduct disorder. A pervasive model was too restrictive, identifying only the most severe disruptive or conduct disordered children. Raising the minimum threshold above eight symptoms (DSM-III-R) missed less disruptive children who nevertheless exhibit significant functional impairment. There was minimal support for the independence of a syndrome of attention deficit disorder without hyperactivity (DSM-III). Finally, ADHD patients commonly have other diagnoses, most frequently conduct disorder, oppositional defiant disorder, and anxiety disorder.
Subject(s)
Attention Deficit Disorder with Hyperactivity/diagnosis , Child Behavior Disorders/diagnosis , Achievement , Attention Deficit Disorder with Hyperactivity/complications , Child , Child Behavior Disorders/classification , Child Behavior Disorders/complications , Comorbidity , Female , Humans , Male , Psychiatric Status Rating Scales , Wechsler ScalesSubject(s)
Attention Deficit Disorder with Hyperactivity/diagnosis , Adolescent , Attention Deficit Disorder with Hyperactivity/psychology , Child , Child Behavior Disorders/diagnosis , Child Behavior Disorders/psychology , Diagnosis, Differential , Humans , Impulsive Behavior/diagnosis , Impulsive Behavior/psychology , Psychiatric Status Rating ScalesABSTRACT
This study reviewed 158 consecutive admissions to an inpatient adolescent psychiatric service for factors that determine length of hospitalization. Variables associated with length of stay included diagnostic category and the treatment variables of number and type of psychotropic medications prescribed. Patients with disruptive behavior disorders had the shortest hospitalizations, those with anxiety and affective disorders had stays of intermediate length, and patients with psychotic/organic disorders had the longest hospitalizations. Treatment with lithium, neuroleptics, or tricyclic antidepressants was associated with longer stays. Demographic variables and variables describing the social and family situation or level of dangerousness were not significantly associated with length of hospitalization.
Subject(s)
Dangerous Behavior , Length of Stay , Mental Disorders/psychology , Mental Disorders/therapy , Personality Development , Social Environment , Adolescent , Female , Humans , Male , Neurocognitive Disorders/psychology , Neurocognitive Disorders/therapy , Psychotropic Drugs/therapeutic useABSTRACT
The ratio of growth hormone response to clonidine and L-dopa challenge was compared in 74 boys: 15 with purported physical abuse, 7 with purported sexual abuse, 13 normal controls, and 39 psychiatric controls. Sexually abused boys demonstrate a statistically significant elevated ratio of growth hormone response to clonidine versus response to L-dopa. Physically abused boys demonstrate lower clonidine/L-dopa growth hormone response ratios compared with controls. These effects widen with increasing physical development.
Subject(s)
Child Abuse, Sexual/blood , Child Abuse/blood , Clonidine , Growth Hormone/blood , Levodopa , Adolescent , Child , Child Abuse/psychology , Child Abuse, Sexual/psychology , Humans , Insulin-Like Growth Factor I/metabolism , Male , Sexual Maturation/physiologyABSTRACT
Studies have shown abnormal pituitary hormone responses to neuroendocrine agonists in autistic subjects. Two probes (clonidine and L-Dopa) were used to investigate neuroendocrine responses through changes in growth hormone levels. Seven medication-free autistic subjects (ages 6.6 to 19.1) were evaluated and compared to 14 normal controls. Growth hormone was collected at 30-min intervals during the entire study. Clonidine was administered first (dose: 0.15 mgm2), and samples were collected for 180 min. L-Dopa was then administered (dose: 250 mg for subjects less than 70 lb and 500 mg for subjects greater than 70 lb), and samples were collected for 120 min. There was no difference in the amplitude of the clonidine or L-Dopa peak growth hormone responses in the control versus the autistic subjects. In the autistic subjects, the L-Dopa-stimulated growth hormone peak was delayed and the clonidine growth hormone peak was premature. A statistical difference with the control subjects was found when consideration was given to both the premature response of growth hormone to clonidine and the delayed response to L-Dopa (p = .01, Fisher's Exact Test). These findings suggest possible abnormalities of both dopaminergic and noradrenergic neurotransmission in subjects with autism.
Subject(s)
Autistic Disorder/blood , Clonidine , Growth Hormone/blood , Levodopa , Adolescent , Autistic Disorder/diagnosis , Autistic Disorder/psychology , Child , Humans , Male , Pilot ProjectsABSTRACT
Two studies compared alprazolam and imipramine in the treatment of school refusal. In an open label study (N = 17), two-thirds of the subjects completing a trial in both the alprazolam and imipramine groups showed moderate to marked global improvement in symptoms of anxiety and depression. In the double-blind, placebo-controlled study (N = 24), posttreatment scores calculated as change from baseline on the Anxiety Rating for Children were significantly different (p = .03) among the three treatment groups, with the active medication groups showing the most improvement. Additionally, on all depression rating scales, similar trends were evident with the alprazolam and imipramine groups demonstrating greater improvement than the placebo group. However, analyses of covariance (with pretreatment scores as the covariates) showed no significant differences among the three treatment groups on change in anxiety and depression scales. Thus, additional research is needed to determine whether trends in this study are explained by drug effect or baseline differences on rating scales.
Subject(s)
Alprazolam/therapeutic use , Imipramine/therapeutic use , Phobic Disorders/drug therapy , Adjustment Disorders/drug therapy , Adolescent , Anxiety Disorders/drug therapy , Child , Depressive Disorder/drug therapy , Double-Blind Method , Female , Humans , Male , Psychiatric Status Rating ScalesABSTRACT
The growth hormone response to stimulation with oral clonidine and L-dopa was measured in 14 boys with major depressive disorder (MDD) and 15 normal boys. The six MDD boys who were prepubertal or in early puberty were significantly lower than the 10 normal subjects of this age in peak growth hormone response following clonidine administration (p = 0.029) and area under the curve for clonidine (p = 0.030) and L-dopa (p = 0.028). The eight later puberty MDD boys did not differ from the five later puberty normal boys on any measures.
Subject(s)
Depressive Disorder/blood , Growth Hormone/blood , Brain/physiopathology , Child , Clonidine , Humans , Levodopa , Receptors, Adrenergic, alpha/physiology , Receptors, Dopamine/physiologyABSTRACT
Of a consecutive series of 115 boys diagnosed in a university outpatient clinic as ADHD, 39% also demonstrated a specific reading disability. Pure ADHD patients were compared with mixed ADHD + RD and normal controls on a battery of cognitive and attentional measures. The aim was to determine whether a distinct pattern of deficits would distinguish the groups. Both ADHD subgroups performed significantly worse than controls on measures of sequential memory and attentional tasks involving impulse control and planful organization. Only ADHD + RD boys differed from controls on measures or rapid word naming and vocabulary. The results are discussed within the framework of an automatic versus effortful information-processing model.
Subject(s)
Attention Deficit Disorder with Hyperactivity/complications , Dyslexia/complications , Referral and Consultation , Achievement , Adolescent , Attention , Attention Deficit Disorder with Hyperactivity/psychology , Child , Concept Formation , Dyslexia/psychology , Humans , Male , Phonetics , Problem Solving , Psychological TestsABSTRACT
Seventy-six families of children with school phobia were evaluated with the Family Assessment Measure. Mothers and fathers, as separate groups, rated clinically significant dysfunction in the parent-child relationship in the areas of role performance and values and norms. There were no significant differences between intact and single-parent families on ratings of family dysfunction. There was significantly less family dysfunction as rated by mothers and by children if the child had a diagnosis of pure anxiety disorder compared to families of school phobic children in other diagnostic categories.
Subject(s)
Family , Phobic Disorders/psychology , Adolescent , Anxiety Disorders/psychology , Child , Female , Humans , Male , Mother-Child Relations , Role , Social ValuesABSTRACT
Attention-deficit hyperactivity symptoms are observed by teachers in 9.2% of a nonreferred elementary school population. Two subtypes of attention-deficit hyperactivity disorder (ADHD), a cognitive form and a behavioral form, are identified. The behavioral subtype includes about 80% of those identified and is characterized by distinct clinical phenomenology of inattention, impulsivity, and hyperactivity. These children can be described on a continuum of severity, with the most severe showing behavioral features indistinguishable from conduct disorder. Children with behavioral subtypes of ADHD do not exhibit the specific skill deficits on neuropsychological tests that are characteristic of reading disabled children. There is a second, less prevalent type of cognitive attention-deficit hyperactivity disorder constituting approximately 20% of ADHD children that includes severe academic underachievement along with inattention, impulsivity, and overactivity. Children with the cognitive subtype exhibit information processing deficits that involve inadequate encoding and retrieval of linguistic information, characteristic of reading disabilities.
Subject(s)
Attention Deficit Disorder with Hyperactivity/diagnosis , Child Behavior Disorders/diagnosis , Learning Disabilities/diagnosis , Adolescent , Child , Dyslexia/diagnosis , Female , Humans , Male , Psychiatric Status Rating Scales , PsychometricsABSTRACT
Buspirone is a novel antianxiety agent with no chemical similarity to other psychotropic medications. Pharmacological effects include inhibition of serotonin neurons, decrease of striatal levels of serotonin and metabolites, and reduction in serotonin binding sites. Buspirone also has effects on dopamine, norepinephrine, and the GABA systems. To pursue an antiserotonergic treatment rationale for autistic disorder, an open-blind 4-week trial comparing buspirone to fenfluramine or methylphenidate was conducted. Hyperactivity was a target symptom in three children with improvement noted in two with buspirone. Behavioral toxicity was encountered in one of two autistic subjects treated with methylphenidate and very mild improvement in another subject on fenfluramine. An autistic child with obsessive ideation was unchanged. No adverse reaction to buspirone was encountered. Further investigation in a double-blind trial of buspirone is warranted for treatment of symptoms of autism, especially aggression and hyperactivity.
Subject(s)
Autistic Disorder/drug therapy , Buspirone/therapeutic use , Autistic Disorder/psychology , Child , Female , Fenfluramine/therapeutic use , Humans , Male , Methylphenidate/therapeutic useABSTRACT
In a study of 988 adolescents, female gender, somatic complaints, history of physical and sexual abuse, poor grades, use of street drugs, and family history related to depression were among factors that differentiated adolescents reporting high anxiety from those reporting low anxiety.
Subject(s)
Anxiety/epidemiology , Personality Inventory , Adolescent , Age Factors , Anxiety/diagnosis , Anxiety/psychology , Child Abuse/psychology , Child Abuse, Sexual/psychology , Depressive Disorder/genetics , Diagnosis, Differential , Female , Humans , Male , Sex FactorsSubject(s)
Suicide/psychology , Adolescent , Age Factors , Child , Female , Humans , Life Change Events , Male , Minnesota , Sex Factors , Suicide/epidemiologyABSTRACT
The purpose of this study was to collect descriptive information on a large number of children, adolescents and young adults who had committed suicide. The medical examiner's records for deaths of persons 25 and under from non-natural causes were reviewed; 656 youth suicides were identified. Children, adolescents and young adults who committed suicide were most likely to be older males with a current psychiatric disorder, usually an affective disorder or alcohol or drug abuse. Suicides appeared to be impulsive and triggered by age-normative precipitants. Sex, age and cohort differences are presented. Results are evaluated in light of previous research.
Subject(s)
Suicide/psychology , Adolescent , Adult , Age Factors , Cause of Death , Female , Humans , Life Change Events , Male , Mental Disorders/psychology , Minnesota , Risk Factors , Sex Factors , Suicide/epidemiologySubject(s)
Asphyxia/diagnosis , Sexual Behavior , Adolescent , Adult , Asphyxia/psychology , Humans , Male , Paraphilic Disorders/psychology , Parent-Child Relations , Suicide/psychologyABSTRACT
This article summarizes the existing neuroendocrine literature and reports the growth hormone response to stimulation with L-dopa and clonidine in male children and adolescents with attention deficit hyperactivity disorder. Because growth hormone secretion is regulated by monoamine neurotransmitters, hyposecretion of growth hormone may reflect generalized changes in the neurochemical substrate of this disorder. With refinement, these neuroendocrine challenge tests may become unique biologic markers in identifying attention deficit hyperactivity disorder in children and adolescents.
Subject(s)
Attention Deficit Disorder with Hyperactivity/physiopathology , Neurosecretory Systems/physiopathology , Attention Deficit Disorder with Hyperactivity/etiology , Child , Humans , Male , Neurotransmitter Agents/physiologyABSTRACT
This article summarizes the existing neuroendocrine literature and reports the growth hormone response to stimulation with L-dopa and clonidine in male children and adolescents with attention deficit hyperactivity disorder. Because growth hormone secretion is regulated by monoamine neurotransmitters, hyposecretion of growth hormone may reflect generalized changes in the neurochemical substrate of this disorder. With refinement, these neuroendocrine challenge tests may become unique biologic markers in identifying attention deficit hyperactivity disorder in children and adolescents.
Subject(s)
Attention Deficit Disorder with Hyperactivity/physiopathology , Growth Hormone/blood , Adolescent , Attention Deficit Disorder with Hyperactivity/etiology , Child , Clonidine , Humans , Levodopa , MaleABSTRACT
Family pedigrees of six children with severe school phobia compared with those of a matched group of families of five children with psychiatric disorders showed a clustering of affective and anxiety disorders. Blind and independent family histories and structured interviews of parents and siblings demonstrated higher rates of depressive and anxiety disorders in first-degree relatives of children with school phobia. Parents of children with school phobia described more disturbance in family functioning on the Family Assessment Measure than did parents in the comparison group in the areas of role performance, communication, affective expression, and control.
